Peripheral administration of antithymocyte globulins: A review of current literature

Transplantation Reviews - Tập 27 - Trang 17-20 - 2013
Matthew Wolf1, Jillian L. Descourouez1, David R. Hager1, Arjang Djamali2
1Pharmacy Department, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
2Department of Medicine, Division Chief of Nephrology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA

Tài liệu tham khảo

Thymoglobulin [Package Insert]. Cambridge, MA, Genzyme Corporation, 2008.

Atgam [Package Insert]. New York, NY, Pfizer, 2005.

Hardinger, 2006, Rabbit antithymocyte globulin induction therapy in adult renal transplantation, Pharmacotherapy, 26, 1771, 10.1592/phco.26.12.1771

Mourad, 2012, The role of Thymoglobulin induction in kidney transplantation: an update, Clin Transplant, 26, E450, 10.1111/ctr.12021

Bhutta ST, Culp WC. Evaluation and management of central venous access complications. Tech Vasc Interv Radiol. United States, Elsevier Inc, 2011, pp 217–24.

Cantarovich, 1994, Tolerance of peripheral veins to antithymocyte globulin after heart transplantation, J Heart Lung Transplant, 13, 737

Rahman, 2000, Administration of equine anti-thymocyte globulin via peripheral vein in renal transplant recipients, Transplantation, 69, 1958, 10.1097/00007890-200005150-00038

Wiland, 1999, Peripheral and outpatient administration of antithymocyte globulin (Atgam(R)), Transplantation, 67, S185, 10.1097/00007890-199904150-00741

Wiland AM, Fink JC, Philosophe B, et al. Peripheral administration of thymoglobulin for induction therapy in pancreas transplantation. Transplant Proc. United States, 2001, p 1910

Marvin, 2003, Administration of rabbit antithymocyte globulin (thymoglobulin) in ambulatory renal-transplant patients, Transplantation, 75, 488, 10.1097/01.TP.0000047313.06232.D3

Erickson AL, Roberts K, Malek SK, Chandraker AK, Tullius SG, Gabardi S. Analysis of infusion-site reactions in renal transplant recipients receiving peripherally administered rabbit antithymocyte globulin as compared with basiliximab: Transpl Int. England, 2010, pp 636-40.

Mathis AS, Rao V. Deep vein thrombosis during rabbit antithymocyte globulin administration. Transplant Proc. United States, 2004, pp 3250–1.

Trofe-Clark, 2012

Mourad, 2001, Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression, Transplantation, 72, 1050, 10.1097/00007890-200109270-00012

Bonnefoy-Berard, 1991, Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins, Transplantation, 51, 669, 10.1097/00007890-199103000-00024

Preville, 2001, Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model, Transplantation, 71, 460, 10.1097/00007890-200102150-00021

Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation. United States, 2008, pp 947-52.

Buchler, 2003, Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy, Clin Transplant, 17, 539, 10.1046/j.1399-0012.2003.00102.x

Kim JM, Jang HR, Ko JS, et al. Comparison between thymoglobulin and ATGAM as an induction agent in adult kidney transplantation: a single-center experience. Transplant Proc. United States, 2012. Published by Elsevier Inc., 2012, pp 171-4.

Gaber, 1998, Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation, Transplantation, 66, 29, 10.1097/00007890-199807150-00005

Trissel, 2003, Physical compatibility of antithymocyte globulin (rabbit) with heparin sodium and hydrocortisone sodium succinate, Am J Health Syst Pharm, 60, 1650, 10.1093/ajhp/60.16.1650

Sollinger, 1995, Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group, Transplantation, 60, 225, 10.1097/00007890-199508000-00003

Puig JM, Lloveras J, Fernandez-Crespo P, et al. Mycophenolate mofetil, ATG, and cyclosporine in the induction treatment of renal transplant recipients minimizes the incidence of acute rejection episodes. Transplant Proc. United States, 1998, pp 2226-7.

O'Grady NP, Alexander M, Burns LA, et al.: Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control. United States, 2011, pp S1-34.

Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc. United States, 2006, pp 1159-71.

Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW and Lipsett PA: Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg. United States, 2001, pp 229-34.

Warren, 2006, Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital, Crit Care Med, 34, 2084, 10.1097/01.CCM.0000227648.15804.2D

Blot SI, Depuydt P, Annemans L, et al. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis. United States, 2005, pp 1591-8.

Periard D, Monney P, Waeber G, et al. Randomized controlled trial of peripherally inserted central catheters vs. peripheral catheters for middle duration in-hospital intravenous therapy. J Thromb Haemost. England, 2008, pp 1281-8.

Thông tin
Thông tin xuất bản

Transplantation Reviews

Tập 27

17-20

Thông tin tác giả